BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers,
Growth Capitalist (https://growthcapitalist.com/2017/10/nw-bio-reports-favorable-results-and-progress-in-resolving-lawsuits-2/)
BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers,